<DOC>
	<DOCNO>NCT01064440</DOCNO>
	<brief_summary>The purpose study evaluate whether intramuscular injection VM202 calf safe effective treatment critical limb ischemia .</brief_summary>
	<brief_title>Safety Efficacy Study Using Gene Therapy Critical Limb Ischemia</brief_title>
	<detailed_description>In absence revascularization option , patient CLI require amputation within 6 month . Patients require major amputation face diminish quality life , unfavorable natural history need extensive resource post-amputation rehabilitation course . The 1-year amputation-free survival rate patient diagnose CLI 45 % ; mortality rate approximately 25 % may high 45 % undergone amputation . Management end-stage disease process consume significant amount healthcare resource . Clearly , new therapeutic approach require . Hepatocyte growth factor ( HGF ) show potent angiogenic growth factor stimulate growth endothelial cell migration vascular smooth muscle cell . Because pluripotent capability , increase availability HGF ischemic tissue achieve therapeutic angiogenesis grow area research . This study use VM202 , DNA plasmid contains novel genomic cDNA hybrid human HGF coding sequence ( HGF-X7 ) express two isoforms HGF , HGF 728 HGF 723 . As currently approve drug reverse CLI patient exhaust surgical endovascular intervention option , induce angiogenesis affect limb VM202 may result increase tissue perfusion , , turn improve wound healing , reduce pain improve limb salvage rate .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Male female , 18 90 year age ; Diagnosis critical limb ischemia ( Rutherford Class 4 5 ) , include : A rest ankle systolic pressure ( either dorsalis pedis posterior tibial artery ) ≤ 70 mmHg affect limb ; A rest toe systolic pressure ≤ 50 mmHg affect limb ; For patient measurement ankle systolic pressure feasible ( e.g . vessel calcification noncompressibility ) ; TcPO2 ≤ 30 mmHg ; Poor suboptimal candidate bypass graft surgery percutaneous angioplasty ; Pain rest , and/or ischemic ulcer , and/or focal gangrene ( &lt; 3 cm2 ) minimum 2 week , Significant stenosis ( ≥ 75 % ) one follow artery : superficial femoral , popliteal , two infrapopliteal artery verify angiography within 12 month prior enrollment ; Be willing maintain current drug therapy peripheral arterial disease throughout course study include antiplatelet statin treatment unless tolerate ; Clinically stable optimize medical regimen &gt; 30 day Be capable understand comply protocol signing informed consent document prior subject study related procedure ; Women surgically sterile least 1 year postmenopausal practice adequate contraception least 12 week prior enter study . If subject childbearing potential , must negative urine pregnancy test result prior study enrollment must agree repeat pregnancy screen test study . If subject subject 's partner ( ) child bear potential , subject subject 's partner ( ) must agree use `` double barrier '' method birth control participate study . Subjects undergone successful revascularization procedure sympathectomy within 12 week prior study entry . A clinically unsuccessful revascularization procedure define one : target vessel reoccludes ( ≥50 % , verified second angiogram . Duplex ultrasonography use determine vessel patency patient tolerate second angiogram ) , target vessel remain patent , resolution symptom 6 week procedure ( e.g . evidence ulcer healing , improvement pressure , reduction rest pain ) ; Subjects require amputation target leg within 4 week randomization ; Subjects evidence active infection ( e.g. , cellulitis , osteomyelitis ) deep ulceration expose bone tendon extremity plan treatment ; Heart Failure NYHA classification III IV ; Stroke ( NIH scale &gt; 2 ) myocardial infarction within last 3 month ; Unstable angina Uncontrolled hypertension define sustain systolic blood pressure ( SBP ) &gt; 200 mmHg diastolic BP ( DBP ) &gt; 110 mmHg baseline/screening evaluation ; Ophthalmologic condition pertinent proliferative retinopathy condition preclude standard ophthalmologic examination ; Inflammatory disorder blood vessel ( inflammatory angiopathy , Buerger 's disease ) ; Subjects advance liver disease include decompensated cirrhosis , jaundice , ascites bleed varix ; Subjects currently receive immunosuppressive medication chemotherapy , radiation therapy ; Positive HIV HTLV screening ; Active Hepatitis B C infection determine Hepatitis B surface antibody ( HBsAb ) , Hepatitis B core antibody ( IgG IgM ; HBcAb ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( AntiHCV ) , Screening ; Specific laboratory value Screening include : Hemoglobin &lt; 8.0 g/dL , WBC &lt; 3,000 cell per microliter , platelet count &lt; 75,000/mm3 , AST and/or ALT &gt; 3 time upper limit normal clinically significant lab abnormality opinion investigator exclusionary ; Patients recent history ( &lt; 5 year ) new screen find malignant neoplasm except basal cell carcinoma squamous cell carcinoma skin ( excised evidence recurrence ) ; patient family history colon cancer first degree relative exclude unless undergone colonoscopy last 12 month negative finding ; Elevated PSA unless prostate cancer exclude ; Subjects co morbid condition likely interfere assessment safety efficacy estimate life expectancy le 6 month Subjects require &gt; 81 mg daily acetylsalicylic acid ; If &gt; 81 mg take screening , subject may enrol willing/able switch another medication ; Subjects require regular COX2 inhibitor drug ( ) high dose steroid ( except inhale steroid ) ; Major psychiatric disorder past 6 month ; History drug alcohol abuse / dependence past 2 year ; Use investigational drug treatment past 12 month ; concurrent participation investigational protocol unapproved therapeutic Unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Painful leg</keyword>
	<keyword>Ischemic leg</keyword>
	<keyword>Treatment Claudication</keyword>
	<keyword>Gene therapy</keyword>
</DOC>